ArticleLung India : official organ of Indian Chest Society2026
A pragmatic workflow for advanced NSCLC diagnosis in routine practice: Integrating histopathology, PD-L1 scoring, and EGFR testing.
Article in Lung India : official organ of Indian Chest Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrecision treatment of advanced non-small cell lung carcinoma (NSCLC) requires early biomarker availability, yet routine practice is constrained by small biopsies, sequential testing, and limited resources. We assessed whether PD-L1 and EGFR testing were completed from the initial biopsy using a tissue-efficient reflex workflow integrating histologic subtyping, PD-L1 scoring, EGFR analysis, and tumour-infiltrating lymphocyte (TIL) assessment.
methodsIn this prospective single-arm feasibility study, 50 stage III or IV NSCLC cases were evaluated. Tumours were subtyped using morphology and minimal immunohistochemistry (TTF-1, Napsin A, p40). PD-L1 immunohistochemistry was performed using a locally validated CAL10-based laboratory-developed test and scored by tumour proportion score (TPS) and combined positive score (CPS). Reflex EGFR testing was attempted in adenocarcinomas with adequate tissue. TILs were graded morphologically. Tissue adequacy and biomarker associations were analysed.
resultsSquamous cell carcinoma comprised 56% and adenocarcinoma 44% of cases. Adequate tissue to complete PD-L1 and EGFR testing was available in 59% (13/22) of adenocarcinomas, and was reported within 30 days. EGFR mutations were detected in 31% of tested adenocarcinomas and were associated with TPS <50% and absent TILs. High PD-L1 expression (TPS ≥50%) was observed in 14% of tumours, exclusively in EGFR wild-type cases. TILs were present in 12% of cases and were significantly associated with higher CPS ( P = 0.002), exceeding TPS.
conclusionA biopsy-level reflex workflow enables feasible, tissue-efficient concurrent molecular and immune profiling in advanced NSCLC. Integration of TPS, CPS, TIL assessment, and EGFR testing within a reflex workflow demonstrates the feasibility of coordinated immuno-molecular profiling from limited biopsy tissue in advanced NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.